FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The key to fibrinolysis and thrombolysis
1509PDF: 266HTML: 125 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1044PDF: 140HTML: 40Appendix: 66 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
437PDF: 63HTML: 45Supplementary: 23Appendix: 39 -
PO21 | PSYCHOLOGICAL IMPACT OF CANCER-ASSOCIATED THROMBOSIS: DUAL BURDEN AND IMPLICATIONS FOR QUALITY OF LIFE AND INTEGRATED PATIENT-CENTERED CARE G. Gerotziafas1|4, Y. Mitrou5, M. Marchetti6, P. Las Casa1, A. Tafur7, V. Bitsadze3, J. Khizroeva3, D. Taizhanova8, D. Antic9, C. Frére10, A. Makatsariya3, L. Garderet1|11, A. Escargueil1, C. Ay12, N. Lomatkin13, Z. Tazi-Mezalek14, M. Sassi15, M. Catalano4|16, J. Gligorov1|17, J. Caprini18, P. Van Dreden1|19, J. Fareed2, A. Falanga6 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP)Paris France; 2Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 3Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 4VAS-European Independent Foundation in Angiology/Vascular Medicine Milan Italy; 5Department of Phylosophy, National and Kapodistrian University of Athens, Greece; 6Department of Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy. School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 7Vascular Medicine, Endeavor Health, Evanston, IL, USA; Pritzker School of Medicine, University of Chicago, Chicago, IL 60637, USA; 8Department of Internal Diseases, Karaganda Medical University Non-Commercial Joint Stock Company, Karaganda, Kazakhstan; 9Clinic for Hematology, University Clinical Center of Serbia, Faculty of Medicine University of Belgrade Belgrade Serbia; 10Department of Hematology, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, INSERM UMRS-1166 Institute of Cardiometabolism and Nutrition, Paris, France; 11Clinical Haematology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, APHP, Paris; 12Department of Internal Medicine I, Clinical Division of Haematology and Haemostaseology, Medical University of Vienna, Vienna, Austria; 13Cardiology Division, Central Clinical Hospital of Presidential Administration, Moscow, Russia; 14Department of Internal Medicine, Hématologie Clinique, Centre Hospitalo-Universitaire Ibn Sina, Université Mohammed V de Rabat, Rabat, Morocco; 15Hematology Laboratory of Maternity and Neonatal Center of Monastir, Faculty of Pharmacy of Monastir, Monastir, Tunisia; 16Inter-University Research Center on Vascular Diseases, University of Milan-L Sacco Hospital, Milan, Italy; 17Medical Oncology Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, Paris, France; 18Vascular Surgery, Pritzker School of Medicine at the University of Chicago, Chicago, USA; 19Clinical Research, Diagnostica Stago, Gennevilliers, France
96PDF: 25 -
Anticoagulation in obese patients: challenges and strategies
1852PDF: 271HTML: 198XML: 83 -
PO02 | SYNERGISTIC INTERACTION OF ENDOTHELIAL AND CANCER CELLS IN THE FORMATION AND STRUCTURE OF THE FIBRIN CLOT SHIELDS M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, clinical research, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
92PDF: 17 -
PO54 | CANCER-ASSOCIATED THROMBOSIS IN ASPIRIN-TREATED PATIENTS AFTER ARTERIAL THROMBOSIS: THE COMPASS-ARTECAT-ASA PROSPECTIVE COHORT STUDY G. Gerotziafas1|3|4|5, S. Allakhverdieva6, P. Henrique Fernandes Do Carmo Las Casa1, P. Van Dreden1|2, J. Fareed3, N. Lomakin6 , I. Zotova6, L. Buryachkovskaya7 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France; 2Clinical Research, Diagnostica Stago, Gennevilliers, France; 3Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Chicago, USA; 4Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, The I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 5VAS-European Independent Foundation in Angiology/Vascular Medicine Milan, Italy; 6Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation, Moscow, Russia; 7Federal State Budgetary Institution «National Medical Research Centre of Cardiology Named After Academician E. I. Chazov» of the Ministry of Health of the Russian Federation, Moscow, Russia
86PDF: 24 -
PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems1|5, A.E. Van Diepen1|2|6, EN. Dekker7, Q.P. Janssen7, J.L. Van Dam7, N. Michiels8, C.W.F. Van Eijck9, K.E.P.E. Hermans1|2, B.A. Bonsing8, K.P. Bosscha10, S.A.W. Bouwense11|12, O. R. Busch13|14, H. Ten Cate4|5|15|16, P.P.L.O. Coene17, C.H.J. Van Eijck7, N. Van Es18|19, E. Van Der Harst17, I.H.J.T. De Hingh20, T.M. Karsten21, G. Kazemier13|14, M.B. Van Der Kolk22, B. De Laat3|5, M.S.L. Liem22, J.S.D. Mieog8, V.B. Nieuwenhuijs24, G.A. Patijn24, M. Roest3, H.C. Van Santvoort25, L. Valkenburg-Van Iersel1|2, R. F. De Wilde7, F. Wit26, B.M. Zonderhuis13|14, M.G. Besselink13|14, M.Y.V. Homs6, G. Van Tienhoven14|27, J. W. Wilmink14|28, B. Groot Koerkamp7, J. De Vos-Geelen1|2 | 1Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; 2GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; 3Synapse Research Institute, Department of Functional Coagulation, Maastricht; 4Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; 5Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; 6Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; 7Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; 8Leiden University Medical Center, Department of Surgery, Leiden; 9Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; 10Jeroen Bosch Hospital, Department of Surgery, Den Bosch; 11Maastricht University Medical Center, Department of Surgery, Maastricht; 12Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; 13Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; 14Cancer Center Amsterdam; 15Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; 16Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; 17Maasstad Hospital, Department of Surgery, Rotterdam; 18Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; 19Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; 20Catharina Hospital, Department of Surgery, Eindhoven; 21OLVG, Department of Surgery, Amsterdam; 22Radboud University Medical Center, Department of Surgery, Nijmegen; 23Medisch Spectrum Twente, Department of Surgery, Enschede; 24Isala Oncology Center, Department of Surgery, Zwolle; 25Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; 26Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; 27Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; 28Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands
96PDF: 19 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
123PDF: 27 -
PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology, Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris, France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
95PDF: 21 -
PO09 | CANCER MORTALITY AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Langholm1, N.H. Eide1, K. Hveem2|3|4, N. Van Es5|6, V.M. Morelli1|7, S.K. Braekkan1|7, J.B. Hansen1|7 | 1Thrombosis Research Group, Department of Clinical Medicine, UiT – The Arctic University of Norway, Tromsø, Norway; 2HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway; 3HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway; 4Department of Research, St. Olav University Hospital, Trondheim, Norway; 5Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; 6Amsterdam Cardiovascular Sciences Pulmonary Hypertension and Thrombosis Amsterdam, the Netherlands; 7Thrombosis Research Center, Department of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
93PDF: 17 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
99PDF: 14 -
Platelet-driven remodeling of cancer cell glycoproteins fuels inflammation and metastasis
87PDF: 31Extra Tables: 20Extra Figure 1: 16Extra Figure 2: 17 -
Crosstalk between hemostasis inhibitors and cholesterol biomarkers in multiple sclerosis
2646PDF: 392Supplementary Files: 114 -
When a feminist platelet went to the convention of prostaglandins and thromboxanes
1087PDF: 115HTML: 64Italian version: 64 -
-
PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; 7Universidad Catolica San Antonio de Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology unit, Arles, France; 10Assistance Publique - Hôpitaux de Paris, AGEPS, France; 11Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département de Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France
99PDF: 14 -
-
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
100PDF: 21 -
PO24 | WE ARE JUGGLING MANY POSSIBILITIES: HEALTHCARE PROFESSIONALS’ EXPERIENCES AND PERSPECTIVES ON INTERPRETATION OF PULMONARY EMBOLISM SIGNS AND SYMPTOMS IN PATIENTS WITH LUNG CANCER A.A. Højen1, M. Søgaard1, A.G. Ording1, M.R. Saugbjerg2, T.D. Christensen2|3, H.R. Jacobsen4, L. Jørgensen5, H. Enggaard5 | 1Danish Center for Health Services Research, Aalborg University Hospital; 2Department of Cardiothoracic Surgery, Aarhus University Hospital; 3Department of Clinical Medicine, Aarhus University Hospital; 4Department of Oncology, Aalborg University Hospital; 5Clinical Nursing Research Unit, Aalborg University Hospital, Denmark
104PDF: 16 -
OC13 | VON WILLEBRAND FACTOR PREDICTS POOR OUTCOME IN PANCREATIC CANCER AND MEDIATES TUMOR-ENDOTHELIUM INTERACTIONS FACILITATING METASTASIS B. Ünlü1, Z. Zhao1, N. Joshi1, S. De1, A. Chion1, I. Schoen1, J. O’Donnell1, M. Flick2, M. Fishel3|4, J. O’Sullivan1 | 1School of Pharmacy and Biomolecular Sciences, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; 3IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA; 4Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
100PDF: 20 -
The use of creatine and the development of deep vein thrombosis. A scoping review
8310PDF: 504Supplementary: 168 -
CO19 | Hypercoagulability in wild-type transthyretin amyloidosis: evidence from whole blood thromboelastometry A. Napolitano1, L. Spiezia1, C. Samà1, A. Benetti1, G. Sinigiani2, L. De Michieli2, A. Cipriani2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; 2Department of Cardiothoracic and Vascular Sciences & Public Health, University Hospital of Padua, Italy
444PDF: 0 -
Platelet distribution width is associated with cardiovascular mortality in an adult general population
2761PDF: 420Supplementary Material: 101 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
87PDF: 23 -
PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators
89PDF: 21 -
CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas1,2, M. Marchetti1,3, L. Russo1, C.J. Tartari1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca5, A. Falanga1,3 All on behalf of the Hypercan Investigators | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; 3School of Medicine and Surgery, University of Milan Bicocca, Italy; 4University Vita-Salute San Raffaele, Milan, Italy; 5Fondazione ARTET Onlus, Bergamo, Italy
510PDF: 0 -
PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 I.C. Moschonas, A.D. Tselepis | Atherothrombosis Research Centre, University of Ioannina, Greece
102PDF: 21 -
PO15 | Venous thromboembolism risk associated with midline catheters and peripherally inserted central catheters: a systematic review and meta-analysis D. Santagata1, F. Subri1, F. Dentali1,2, M.P. Donadini1, I. Giarretta2 | 1Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como; 2Department of Internal Medicine, Ospedale di Circolo and Fondazione Macchi, Varese, Italy
441PDF: 0 -
PO17 | PREDICTIVE VALUE OF INFLAMMATORY AND ENDOTHELIAL BIOMARKERS FOR CANCER RISK IN HEALTHY INDIVIDUALS: EVIDENCE FROM THE HYPERCAN STUDY C. Ticozzi1, S. Bolognini1|2, P. Gomez-Rosas1|3, F. Schieppati1|2, G. Sampietro4, L. Barcella1, M. Marchetti1|2, A. Falanga1|2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
89PDF: 21 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
102PDF: 23 -
PO48 | Thrombotic risk evaluation and thrombophilia testing in β-thalassemia patients: a retrospective cohort analysis from a reference regional center G.M. Camarda1,2*, S. Raso1*, R. Di Maggio1, M. Vinciguerra3, A. Giangreco1, A. Inzerillo1, A. Maggio, M. Napolitano1,2 | *These authors contributed equally to this abstract; 1Hematology and Rare Diseases Unit, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo; 2Division of Hematology Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “ProMISE”, Palermo; 3UOSD Molecular Diagnosis of Rare Blood Diseases, Azienda Ospedaliera, Ospedali Riuniti Villa Sofia, Cervello, Palermo, Italy
510PDF: 0 -
PO35 | A MULTICENTRE AUDIT OF CURRENT TUMOUR THROMBOSIS MANAGEMENT IN THE UNITED KINGDOM A.A. Bhatti1, L. Tafesh1, A. Waton1, M. Thomas3, N. Prasannan3, A. Bhide3, R. Walsh3, T. Lucas3, K. White4, T. Bariana4, O. Tsiamita4, S. Soman4, P. Woolley5, I. Lacej5, K. Musgrave1|2 | 1Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 2Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 3University College London Hospitals NHS Foundation Trust, London, UK; 4Barts Health NHS Trust, London, UK; 5Imperial College Healthcare NHS Trust, London, UK
105PDF: 16 -
CO14 | Inflammation and fibrinolysis biomarkers as predictors of cancer risk in healthy subjects: results from the hypercan study C. Ticozzi1, S. Bolognini1,2, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
510PDF: 0 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
103PDF: 21 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1299PDF: 226HTML: 87Supplementary: 65 -
“Living under the sword of Damocles”: a psychological support project for patients with immune thrombocytopenia and their caregivers
815PDF: 268Appendix A: 88Appendix B: 116 -
CO46 | Comparison of reticulated platelet procoagulant role in liver cirrhosis vs. fibrosis S. Toffanin1, E. Campello1, A. Zanetto2, G. Gagliardi1, A. Napolitano1, E. Stocco1, G. Gobbo1, E. Pinto2, C. M. Radu1, M. Senzolo2, L. Fabris1, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padova; 2Department of Surgery Oncology and Gastroenterology, Gastroenterology and Multivisceral Transplant Unit, Padova University Hospital, Padova, Italy
458PDF: 0 -
PO16 | EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES OF PROVOKED AND UNPROVOKED PULMONARY EMBOLISM IN A MULTICULTURAL ISRAELI POPULATION R. Farah1, N.L. Bragazzi2|3|4, H.İ. Ceylan5, Ł. Szarpak6|7|8|9, W. Mahajni1, N. Ashqar1, A. M. Fioretti10, R. Khamisy-Farah11 | 1Internal Medicine B Department, Ziv Medical Center, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel; 2Laboratory for Industrial and Applied Mathematics, Department of Mathematics and Statistics, York University, Toronto, Canada; 3Postgraduate School of Public Health, Department of Health Sciences, University of Genoa, Italy; 4UNESCO Chair, Health Anthropology, Biosphere and Healing Systems, University of Genoa, Italy; 5Physical Education and Sports Teaching Department, Faculty of Sports Sciences, Atatürk University, Erzurum, Turkey; 6Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; 7Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland; 8The World Academic Council of Emergency Medicine, Sarasota, FL, USA; 9Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA; 10Cardio-Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; 11Clalit Health Service, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel
105PDF: 24 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
497PDF: 0 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
599PDF: 0 -
PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Antoun1, J. Hansen1|3, S. Brækkan1|3, C. Langholm1, N. Eide1, V. Morelli1|3, K. Hveem2 | 1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø; 2HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim; 3Thrombosis Research Center, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
98PDF: 18 -
CO44 | First interlaboratory validation workshop of immunofluorescence microscopy on the peripheral blood smear for recognizing patients with inherited platelet disorders C. Zaninetti1, L. Bury2, V. Bozzi3, A. Zamora-Cánovas4, K. Althaus5, G. Uzun5, S. Brown6, A. Norman6, D. Faille7, A. Stepanian8, C. Freyer1, L. Kager9, T. Bakchoul5, A. Pecci3, P. Gresele2, T. Thiele1, J. Rivera4, A. Greinacher1 | 1Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Germany; 2Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 3Department of Internal Medicine, University of Pavia, Italy; General Medicine 1, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; 4Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonacio´n, Universidad de Murcia, Spain; 5Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tuebingen, Germany; Center for Clinical Transfusion Medicine, Tuebingen, Germany; 6Centre for Children’s Health and Research CCHR, South Brisbane, Australia; 7Laboratoire d’Hématologie, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Paris, France; 8AP-HP, Service d’Hématologie Biologique, Hôpital Lariboisière, Paris Cité University, Paris, France; 9St. Anna Kinderspital, Universitätsklinik für Kinder- und Jugendheilkunde der Medizinischen Universität Wien, Austria
458PDF: 0 -
PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY D. Siegal1|2, Z. O’Neill1|2, L. Nguyen3, N. Liu3, M. Carrier1|2, R. Sutradhar3|4 | 1Ottawa Hospital Research Institute, Ottawa; 2Department of Medicine, University of Ottawa, Ottawa; 3ICES, Toronto, Canada; 4Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
106PDF: 20 -
PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE) M. Napolitano1, M. Mattana2, C. Cammarata1, M. Leotta3, S. Linari4, M.E. Mancuso5, G. F. Rivolta6, C. Santoro7, L. Valdrè8, R.C. Santoro3, S. Siragusa1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; 2Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; 4Center for Bleeding Disorders, Careggi University Hospital, Firenze; 5Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; 6Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; 7Hematology, University Hospital Policlinico Umberto I, Roma; 8Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy
555PDF: 0 -
PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA I. Goldberg1|2, P. Raanani1|2|3, G. Spectre1|2 | 1Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
99PDF: 17 -
CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects S. Bolognini1,2, C. Ticozzi1, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
526PDF: 0 -
CO39 | Artificial intelligence in hemophilia management: challenging the need for experts G. Sottilotta1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria; 2Laboratorio Analisi, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
470PDF: 0 -
PO41 | Comparison of the haemorrhagic phenotype between female and male patients affected by autosomal inherited bleeding disorders in a single-centre cohort B. Borsellino1,3, C. Zuccotti2, L. Guarnera3,4, C. Biasoli5, P. Pedrazzi5, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin, Italy; 2Department of Clinical Pathology, Bufalini Hospital, Cesena, Italy; 3Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy; 4Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 5Haemophilia and Transfusion Centre, Bufalini Hospital, Cesena, Italy
480PDF: 0
